Evidence for HIV-1 cure after CCR5 Delta 32/Delta 32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report


Por: Gupta, RK, Peppa, D, Hill, AL, Galvez, C, Salgado, M, Pace, M, McCoy, LE, Griffith, SA, Thornhill, J, Alrubayyi, A, Huyveneers, LEP, Nastouli, E, Grant, P, Edwards, SG, Innes, AJ, Frater, J, Nijhuis, M, Wensing, AMJ, Martinez-Picado, J and Olavarria, E

Publicada: 1 may 2020
Resumen:
Background The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5 Delta 32/Delta 32); remission was reported at 18 months after analytical treatment interruption (ATI). Here, we present longer term data for this patient (up to 30 months after ATI), including sampling from diverse HIV-1 reservoir sites. Methods We used ultrasensitive viral load assays of plasma, semen, and cerebrospinal fluid (CSF) samples to detect HIV-1 RNA. In gut biopsy samples and lymph-node tissue, cell-copy number and total HIV-1 DNA levels were quantified in multiple replicates, using droplet digital PCR (ddPCR) and quantitative real-time PCR. We also analysed the presence of intact proviral DNA using multiplex ddPCR targeting the packaging signal (psi) and envelope (env). We did intracellular cytokine staining to measure HIV-1-specific T-cell responses. We used low-sensitive and low-avidity antibody assays to measure the humoral response to HIV-1. We predicted the probability of rebound using a mathematical model and inference approach. Findings HIV-1 viral load in plasma remained undetectable in the London patient up to 30 months (last tested on March 4, 2020), using an assay with a detection limit of 1 copy per mL. The patient's CD4 count was 430 cells per mu L (23.5% of total T cells) at 28 months. A very low-level positive signal for HIV-1 DNA was recorded in peripheral CD4 memory cells at 28 months. The viral load in semen was undetectable in both plasma (lower limit of detection [LLD] <12 copies per mL) and cells (LLD 10 copies per 10(6) cells) at 21 months. CSF was within normal parameters at 25 months, with HIV-1 RNA below the detection limit (LLD 1 copy per mL). HIV-1 DNA by ddPCR was negative in rectum, caecum, and sigmoid colon and terminal ileum tissue samples at 22 months. Lymph-node tissue from axilla was positive for the long-terminal repeat (33 copies per 10(6) cells) and env (26.1 copies per 106 cells), negative for psi and integrase, and negative by the intact proviral DNA assay, at 27 months. HIV-1-specific CD4 and CD8 T-cell responses have remained absent at 27 months. Low-avidity Env antibodies have continued to decline. Mathematical modelling suggests that the probability of remission for life (cure) is 98% in the context of 80% donor chimerism in total HIV target cells and greater than 99% probability of remission for life with 90% donor chimerism. Interpretation The London patient has been in HIV-1 remission for 30 months with no detectable replication-competent virus in blood, CSF, intestinal tissue, or lymphoid tissue. Donor chimerism has been maintained at 99% in peripheral T cells. We propose that these findings represent HIV-1 cure. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.

Filiaciones:
Gupta, RK:
 Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England

 Africa Hlth Res Inst, Durban, South Africa

Peppa, D:
 Univ Oxford, Nuffield Dept Med, Oxford, England

 UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice, London, England

Hill, AL:
 Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA

:
 irsiCaixa AIDS Res Inst, Badalona, Spain

 Autonomous Univ Barcelona, Cerdanyola Del Valles, Spain

:
 irsiCaixa AIDS Res Inst, Badalona, Spain

Pace, M:
 Univ Oxford, Nuffield Dept Med, Oxford, England

McCoy, LE:
 Univ Coll London UCL, Div Infect & Immun, London, England

Griffith, SA:
 Univ Coll London UCL, Div Infect & Immun, London, England

Thornhill, J:
 Imperial Coll London, London, England

Alrubayyi, A:
 Univ Oxford, Nuffield Dept Med, Oxford, England

Huyveneers, LEP:
 Univ Med Ctr, Dept Med Microbiol, Utrecht, Netherlands

Nastouli, E:
 Univ Coll London UCL, Div Infect & Immun, London, England

 UCL Hosp, Dept Virol, London, England

 UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice, London, England

Grant, P:
 UCL Hosp, Dept Virol, London, England

Edwards, SG:
 Cent & North West London NHS Trust, Dept HIV, Mortimer Market Ctr, London, England

Innes, AJ:
 Imperial Coll London, London, England

 Hammersmith Hosp, Imperial Coll NHS Healthcare Trust, London, England

Frater, J:
 Univ Oxford, Nuffield Dept Med, Oxford, England

 Oxford Natl Inst Hlth, Res Biomed Res Ctr, Oxford, England

Nijhuis, M:
 Univ Med Ctr, Dept Med Microbiol, Utrecht, Netherlands

Wensing, AMJ:
 Univ Med Ctr, Dept Med Microbiol, Utrecht, Netherlands

:
 irsiCaixa AIDS Res Inst, Badalona, Spain

 Univ Vic, Cent Univ Catalonia, Vic, Spain

 Catalan Inst Res & Adv Studies, Barcelona, Spain

Olavarria, E:
 Imperial Coll London, London, England

 Cent & North West London NHS Trust, Dept HIV, Mortimer Market Ctr, London, England
ISSN: 24054704





Lancet HIV
Editorial
Elsevier Ltd., 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA, Reino Unido
Tipo de documento: Article
Volumen: 7 Número: 5
Páginas: 340-347
WOS Id: 000531088000016
ID de PubMed: 32169158
imagen Green Published, hybrid

MÉTRICAS